Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-092274
Filing Date
2024-08-07
Accepted
2024-08-07 07:13:37
Documents
65
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tngx-20240630.htm   iXBRL 10-Q 1648097
2 EX-3.1 tngx-ex3_1.htm EX-3.1 81569
3 EX-10.1 tngx-ex10_1.htm EX-10.1 19449
4 EX-31.1 tngx-ex31_1.htm EX-31.1 16355
5 EX-31.2 tngx-ex31_2.htm EX-31.2 16288
6 EX-32.1 tngx-ex32_1.htm EX-32.1 7926
7 EX-32.2 tngx-ex32_2.htm EX-32.2 7917
  Complete submission text file 0000950170-24-092274.txt   6779689

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20240630.xsd EX-101.SCH 923373
67 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20240630_htm.xml XML 1143221
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39485 | Film No.: 241181412
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)